Tadalafil and patients preference in the treatment of erectile dysfunction / 中华男科学杂志
National Journal of Andrology
;
(12): 1145-1148, 2006.
Artículo
en Chino
| WPRIM
| ID: wpr-289060
ABSTRACT
ED treatment has changed fundamentally since phosphodiesterase type 5 inhibitor (PDE5-I) came into clinical use. There are three kinds of PDE5-I available at present, Sildenafil, Vardenafil and Tadalafil. Tadalafil distinguishes from the other two by its uniquely long half-life, which lasts 17.5h, which a pharmacodynamic duration of 36h and not influenced by food and alcohol. Thus it may enable ED patients to accomplish a spontaneous intercourse without the need of prior preparation without, which can boost their confidence and self-esteem and, the most important, improve the relationship with their partner. To know patient preference counts quite a lot in optimizing the medication ED treatment.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Inhibidores de Fosfodiesterasa
/
Psicología
/
Psicoterapia
/
Carbolinas
/
Satisfacción del Paciente
/
Usos Terapéuticos
/
Quimioterapia
/
Tadalafilo
/
Disfunción Eréctil
Límite:
Humanos
/
Masculino
Idioma:
Chino
Revista:
National Journal of Andrology
Año:
2006
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS